Shares of clinical-stage biopharmaceutical company Nuvalent (NASDAQ:NUVL) are rising in the pre-market session today on promising Phase 1 data for NVL-520 in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) as well as other solid tumors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The drug is designed to address emergent treatment resistance, off-target central nervous system events as well as brain metastases at the same time.
NVL-520 demonstrated a favorable safety profile as well as a lack of dose reductions or discontinuations in the study.
Shares of the company are now up 30% in the past month alone.
Read full Disclosure